# US 2021/0276996 A1 · Degraders that target proteins via keap1

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0276996 A1
- Document ID: US20210276996A1
- Status: Published application
- Kind: A1
- Application number: 17/258,340
- Filed: 2019-07-18
- Published: 2021-09-09
- Earliest claimed: 2018-07-20
- Assignees: Dana-Farber Cancer Institute, Inc.
- Applicants: Dana-Farber Cancer Institute, Inc.
- Inventors: Nathanael S. Gray; Tinghu Zhang; Eric Fischer; Guangyan Du; Nozhat Safaee; Nathaniel Henning; Katherine Donovan
- Web page: https://patentgrep.com/patent/US20210276996A1

## CPC

- A61K 47/545: {Heterocyclic compounds (A61K47/558 takes precedence)}
- C07D 419/14: containing three or more hetero rings
- A61K 47/55: the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
- C07D 403/12: linked by a chain containing hetero atoms as chain links
- C07D 417/14: containing three or more hetero rings
- C07D 495/14: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Disclosed are bifunctional compounds, pharmaceutical compositions containing them, and methods of making and using them to treat diseases and disorders characterized by aberrant protein activity wherein the protein is targeted for degradation by KEAP1 and the Cul3-based E3-ubiquitin ligase complex.

## Claims

### Claim 1

A bifunctional compound having a structure represented by formula (I):
wherein:
R is methyl or halo;
R1 is
R2 is methyl,
wherein L is a linker and TL is a targeting ligand that binds a protein of interest, or
wherein
R3 is H or
R4 is H, halo or
R5 is methoxy or
R6 is H or methyl; and
R8 is H or ethyl;
provided that one of R2, R3, R4 and R5 is
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 2 (depends on 1)

The bifunctional compound of claim 1, wherein R is methyl;
R1 is
R2 is
wherein
R3 is
R5 is methoxy; and R6 is methyl,
the bifunctional compound is represented by formula (Ia):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 3 (depends on 1)

The bifunctional compound of claim 1, wherein R is methyl;
R1 is
wherein
R4 is
R5 is methoxy; and R8 is H,
the bifunctional compound is represented by formula (Ib):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 4 (depends on 1)

The bifunctional compound of claim 1, wherein R is methyl;
R1 is
R2 is
R5 is methoxy;
R6 is H; and R8 is H,
the bifunctional compound is represented by formula (Ic):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 5 (depends on 1)

The bifunctional compound of claim 1, wherein R is Cl;
R1 is
R2 is
R3 is
R5 is methoxy;
R6 is methyl; and R8 is H,
the bifunctional compound is represented by formula (Id):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 6 (depends on 1)

The bifunctional compound of claim 1, wherein R is Cl;
R1 is
wherein
R2 is
R5 is methoxy;
R6 is H; and R8 is H,
the bifunctional compound is represented by formula (Ie):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 7 (depends on 1)

The bifunctional compound of claim 1, wherein R is methyl;
R1 is
R4 is H; and
R5 is
and R8 is H,
the bifunctional compound is represented by formula (If):
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 8 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds BRD4, BRD3 and BRD2, and wherein the bifunctional compound is represented by a structure selected from the group consisting of:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 9 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds BRD4, BRD3 and BRD2, and wherein the bifunctional compound is represented by a structure selected from the group consisting of:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 10 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds multiple kinases including BTK, FAK, CDK7, CDK9, HCK, ALK, FLT3, EGFR, AAK1, WEE1, LIMK2, AURKA, AURKB, CDK5, ITK, CDK12, CDK13, LCK, GAK, BLK, ULK1 and BLK, and wherein the bifunctional compound is represented by a structure selected from the group consisting of:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 11 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds multiple kinases including BTK, FAK, CDK7, CDK9, HCK, ALK, FLT3, EGFR, AAK1, WEE1, LIMK2, AURKA, AURKB, CDK5, ITK, CDK12, CDK13, LCK, GAK, BLK, ULK1 and BLK, and wherein the bifunctional compound is represented by a structure selected from the group consisting of:
or pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 12 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds Bruton's tyrosine kinase.

### Claim 13 (depends on 12)

The bifunctional compound of claim 12, wherein the compound has the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 14 (depends on 1)

The bifunctional compound of claim 1, wherein the targeting ligand binds KRASG12C.

### Claim 15 (depends on 14)

The bifunctional compound of claim 14, wherein the compound has the structure:
or a pharmaceutically acceptable salt or stereoisomer thereof.

### Claim 16 (depends on 1)

A pharmaceutical composition comprising a therapeutically effective amount of the bifunctional compound of claim 1, and a pharmaceutically acceptable carrier.

### Claim 17 (depends on 1)

A method of treating a disease or disorder characterized by an aberrant or dysfunctional protein, comprising administering to a subject in need thereof a therapeutically effective amount of the bifunctional compound of claim 1.
